Breaking News
Investing Pro 0
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

Published Nov 22, 2019 09:05AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine,
 
SASY
+0.82%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GILD
+2.20%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Matthias Blamont

PARIS (Reuters) - Sanofi's (PA:SASY) most senior strategy boss is set to leave by the end of the month, according to a memo seen by Reuters, in the first major management change under new chief executive Paul Hudson as he shakes up the firm's priorities.

Muzammil Mansuri, head of strategy and business development and member of the French drugmaker's executive committee, will be retiring from the company, according to the note from Hudson sent to staff on Wednesday.

A spokesman for Sanofi confirmed the decision.

Hudson, who took over as CEO on Sept. 1, is leading a strategic review and is expected to unveil the company's plan for the coming years at an investor day in Cambridge, Massachusetts, on December 10.

Mansuri had joined Sanofi in 2016 from Gilead Sciences (O:GILD) where he was in charge of research and development strategy and corporate development.

Hudson said in the memo that Alban de la Sabliere, currently head of business development, and Laurent Van Lerberghe, head of strategy, would take on more responsibilities as of Dec. 1 and report directly to him.

Even though the group's new strategy is still in the works, Hudson has made no secret that significant changes were underway.

"I am bringing a little sense of urgency and prioritization. I have set a tone already that we can move a little bit faster," Hudson told reporters in October.

"I think we have the right level of resources although perhaps not always in the right place."

Sources have told Reuters Sanofi was contemplating a joint venture or an outright sale among options for its consumer healthcare unit.

An initial public offering (IPO) of the business, which could be worth around $30 billion according to two sources familiar with the matter, is also potentially on the cards though they cautioned that no final decision had been made.

Analysts have argued a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion euros ($5.20 billion), would enable the group to invest more in internal research.

The future of Sanofi's ailing diabetes business - under constant pricing pressure in the United States, the world's largest health market - is also under the spotlight.

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email